The excess burden of osteoarthritis in the province of Ontario, Canada
- PMID: 22081470
- DOI: 10.1002/art.33467
The excess burden of osteoarthritis in the province of Ontario, Canada
Abstract
Objective: Little is known about the burden of osteoarthritis (OA) in Canada. This study was undertaken to estimate the excess burden of OA in Ontario, the largest province in Canada.
Methods: The records of Ontarian respondents to the Canadian Community Health Survey (CCHS) who provided consent to data linkage were linked to the Ontario Health Insurance Program physician claims database and the Discharge Abstract Database Inpatient and Day Procedure databases. Patients with OA (n = 1,474) were identified using CCHS 1.1 and the physician claims database. To determine the excess burden of OA, a control group matched by age, sex, and rural/urban status was created, with 3 controls per case (n = 4,422). Sociodemographic and medical characteristics, health-related quality of life, and 1-year physician, day (outpatient) procedure, and hospitalization costs were compared between the 2 groups. Regression analyses were performed to identify predictors of medical characteristics, health utility, and cost.
Results: The mean age of the OA patients and the control subjects was 66 years, and 74% of all study subjects were women. Several differences were observed between patients with OA and subjects without OA in terms of socioeconomic and medical characteristics. On a scale of 0-1, the mean utility value associated with OA was 0.68, compared to 0.84 for the control group (P < 0.0001), representing a utility decrement of 0.16. The 1-year physician, outpatient procedure, and hospitalization costs were significantly higher in the OA group than in the non-OA group ($2,233 Canadian versus $1,033 Canadian, respectively; P < 0.0001).
Conclusion: These results indicate that the excess burden of OA in Ontario is considerable.
Copyright © 2012 by the American College of Rheumatology.
Similar articles
-
The excess burden of rheumatoid arthritis in Ontario, Canada.Clin Exp Rheumatol. 2013 Jan-Feb;31(1):18-24. Epub 2012 Oct 3. Clin Exp Rheumatol. 2013. PMID: 23043846
-
Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.Clin Ther. 2009 Nov;31(11):2653-64. doi: 10.1016/j.clinthera.2009.11.032. Clin Ther. 2009. PMID: 20110008
-
Direct and indirect costs attributable to osteoarthritis in active subjects.J Rheumatol. 2006 Jun;33(6):1152-8. J Rheumatol. 2006. PMID: 16755664
-
Influence of overweight and obesity on physician costs in adolescents and adults in Ontario, Canada.Obes Rev. 2009 Jan;10(1):51-7. doi: 10.1111/j.1467-789X.2008.00514.x. Epub 2008 Jul 18. Obes Rev. 2009. PMID: 18647244 Review.
-
The individual and socioeconomic impact of osteoarthritis.Nat Rev Rheumatol. 2014 Jul;10(7):437-41. doi: 10.1038/nrrheum.2014.44. Epub 2014 Mar 25. Nat Rev Rheumatol. 2014. PMID: 24662640 Review.
Cited by
-
Validity of Algorithms for Identification of Individuals Suffering from Chronic Noncancer Pain in Administrative Databases: A Systematic Review.Pain Med. 2020 Sep 1;21(9):1825-1839. doi: 10.1093/pm/pnaa004. Pain Med. 2020. PMID: 32142130 Free PMC article.
-
Addressing obesity in the management of knee and hip osteoarthritis - weighing in from an economic perspective.BMC Musculoskelet Disord. 2016 May 26;17:233. doi: 10.1186/s12891-016-1087-7. BMC Musculoskelet Disord. 2016. PMID: 27229924 Free PMC article. Review.
-
Cost-Utility of a Single-Injection Combined Corticosteroid-Hyaluronic Acid Formulation vs a 2-Injection Regimen of Sequential Corticosteroid and Hyaluronic Acid Injections.Clin Med Insights Arthritis Musculoskelet Disord. 2017 Jun 12;10:1179544117712993. doi: 10.1177/1179544117712993. eCollection 2017. Clin Med Insights Arthritis Musculoskelet Disord. 2017. PMID: 28638242 Free PMC article.
-
Top 100 Cited Articles on Osteoarthritis from 1990 to 2020.Rheumatol Immunol Res. 2021 Dec 31;2(4):241-248. doi: 10.2478/rir-2021-0033. eCollection 2021 Dec. Rheumatol Immunol Res. 2021. PMID: 36467986 Free PMC article.
-
Safety and pharmacokinetics of EP-104IAR (sustained-release fluticasone propionate) in knee osteoarthritis: A randomized, double-blind, placebo-controlled phase 1 trial.Osteoarthr Cartil Open. 2021 Sep 9;3(4):100213. doi: 10.1016/j.ocarto.2021.100213. eCollection 2021 Dec. Osteoarthr Cartil Open. 2021. PMID: 36474755 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical